The Bio Medica Laboratories IPO is an upcoming SME book-building issue set to be listed on the NSE SME platform, offering a mix of fresh equity shares and an offer for sale totaling around 37.71 lakh shares. The company operates in the pharmaceutical sector, specializing in the manufacturing of parenteral formulations such as liquid and dry powder injectables used for both human and veterinary healthcare. It follows a B2B contract manufacturing model, supplying generic, ethical, and OTC drugs to various pharmaceutical companies. Financially, the company has demonstrated strong growth, with revenue of approximately ₹38 crore and profit after tax of around ₹9.7 crore in FY2025, indicating robust operational performance. The IPO proceeds are expected to be utilized for loan repayment, expansion of manufacturing capacity, and general corporate purposes. While key details like price band and dates are yet to be announced, the IPO presents an opportunity to invest in a growing pharmaceutical manufacturing business in India’s expanding healthcare sector.